ERBB2 and breast carcinoma: In addition, due to the low immunogenicity and the inherent tumor-homing ability, MSCs can be used to load novel nano-chemotherapy drugs to achieve the purpose of targeted delivery to breast cancer cells, providing a new solution for HER2-negative breast cancer targeted drugs (145).